BR112014016085A2 - composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico - Google Patents

composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico

Info

Publication number
BR112014016085A2
BR112014016085A2 BR112014016085A BR112014016085A BR112014016085A2 BR 112014016085 A2 BR112014016085 A2 BR 112014016085A2 BR 112014016085 A BR112014016085 A BR 112014016085A BR 112014016085 A BR112014016085 A BR 112014016085A BR 112014016085 A2 BR112014016085 A2 BR 112014016085A2
Authority
BR
Brazil
Prior art keywords
acetylsalicylic acid
delivery
methods
omeprazole plus
omeprazole
Prior art date
Application number
BR112014016085A
Other languages
English (en)
Other versions
BR112014016085A8 (pt
Inventor
R Plachetka John
Original Assignee
Pozen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48698802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014016085(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pozen Inc filed Critical Pozen Inc
Publication of BR112014016085A2 publication Critical patent/BR112014016085A2/pt
Publication of BR112014016085A8 publication Critical patent/BR112014016085A8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo patente de invenção: "composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico". a presente descrição é dirigida a um método para distribuição de uma composição farmacêutica a um paciente que precisa da mesma compreendendo: administração, ao dito paciente, de uma composição farmacêutica na forma de dose unitária compreendendo ácido acetilsalicílico, ou sal farmaceuticamente aceitável do mesmo, e omeprazol, ou um sal farmaceuticamente aceitável do mesmo.
BR112014016085A 2011-12-28 2012-12-27 composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico BR112014016085A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161580861P 2011-12-28 2011-12-28
US201261585432P 2012-01-11 2012-01-11
PCT/US2012/071759 WO2013101897A2 (en) 2011-12-28 2012-12-27 Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid

Publications (2)

Publication Number Publication Date
BR112014016085A2 true BR112014016085A2 (pt) 2017-06-13
BR112014016085A8 BR112014016085A8 (pt) 2017-07-04

Family

ID=48698802

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014016085A BR112014016085A8 (pt) 2011-12-28 2012-12-27 composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico

Country Status (9)

Country Link
US (3) US9539214B2 (pt)
EP (1) EP2797600A4 (pt)
CN (1) CN104519888A (pt)
BR (1) BR112014016085A8 (pt)
CA (1) CA2860231A1 (pt)
EA (1) EA028049B1 (pt)
MX (1) MX2014007935A (pt)
UA (1) UA115139C2 (pt)
WO (1) WO2013101897A2 (pt)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) 2015-02-10 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695429B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729774B1 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933137B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10537642B1 (en) 2015-02-10 2020-01-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10517950B1 (en) 2015-02-10 2019-12-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10702602B2 (en) 2015-02-10 2020-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729773B2 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10532101B1 (en) 2015-02-10 2020-01-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11110173B2 (en) 2015-02-10 2021-09-07 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10653777B2 (en) 2015-02-10 2020-05-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) 2015-02-10 2020-10-13 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512692B2 (en) 2015-02-10 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695430B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10722583B2 (en) 2015-02-10 2020-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) 2015-02-10 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
TWI710379B (zh) 2015-07-30 2020-11-21 日商武田藥品工業股份有限公司 錠劑
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10561664B1 (en) 2017-01-04 2020-02-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CA3121746A1 (en) 2017-01-04 2018-07-12 Herriot TABUTEAU Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729696B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) 2017-01-04 2021-01-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729697B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583144B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) 2017-06-29 2021-04-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758617B2 (en) 2017-06-29 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11219626B2 (en) 2017-06-29 2022-01-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688185B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688102B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Combination treatment for migraine and other pain
US10512693B2 (en) 2017-06-29 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
JP7211139B2 (ja) * 2019-02-14 2023-01-24 日本電信電話株式会社 校閲方法、情報処理装置および校閲プログラム
US20230190697A1 (en) * 2020-03-31 2023-06-22 Ensysce Biosciences, Inc. Methods for treating viral infections with nafamostat
KR20220040169A (ko) * 2020-09-23 2022-03-30 (주)아이엠디팜 나파모스타트 또는 이의 약제학적으로 허용가능한 염을 포함하는 경구투여용 제제
KR20230125826A (ko) 2020-12-31 2023-08-29 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물
US12005118B2 (en) 2022-05-19 2024-06-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
CH647676A5 (fr) 1978-12-22 1985-02-15 Donald E Panoz Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation.
US4198390A (en) 1979-01-31 1980-04-15 Rider Joseph A Simethicone antacid tablet
FR2470599A1 (fr) 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
US4344929A (en) 1980-04-25 1982-08-17 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
GB2105193B (en) 1981-09-04 1984-09-12 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPS59227870A (ja) 1983-06-07 1984-12-21 Yamanouchi Pharmaceut Co Ltd 新規2−グアニジノチアゾリン誘導体ならびにその製造法
US4554276A (en) 1983-10-03 1985-11-19 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US4522826A (en) 1984-02-08 1985-06-11 Richardson-Vicks Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
IT1196190B (it) 1984-07-12 1988-11-10 Lisapharma Spa Forma farmaceutica solida orale ad azione sequenziale per la somministrazione di farmaci ad effetto collaterale ulcerogeno
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
US4766117A (en) 1984-10-11 1988-08-23 Pfizer Inc. Antiinflammatory compositions and methods
US4704278A (en) 1984-10-17 1987-11-03 American Home Products Corp (Del) Fluidized magaldrate suspension
US4676984A (en) 1985-08-14 1987-06-30 American Home Products Corp. Rehydratable antacid composition
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
DE3603576A1 (de) 1986-02-06 1987-08-13 Code Kaffee Handel Verwendung von gerbstoffen und/oder chlorogensaeure sowie nahrungs-, genuss- und/oder arzneimittel mit gerbstoff- und/oder chlorogensaeurezusatz
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
US5043358A (en) 1986-03-04 1991-08-27 Bristol-Myers Squibb Company Gastroprotective process
US4757060A (en) 1986-03-04 1988-07-12 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers
US5037815A (en) 1986-03-04 1991-08-06 Bristol-Myers Squibb Co. Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers
US4965065A (en) 1986-04-29 1990-10-23 Bristol-Myers Squibb Company Gastroprotective process and compositions
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5260333A (en) 1986-08-08 1993-11-09 Bristol Myers Squibb Company Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
EP0320550A1 (en) 1987-12-18 1989-06-21 Bristol-Myers Company Non steroidal anti-inflammatory drug composition containing H1 blockers, H2 blockers, beta adrenergic agonists or combinations thereof and an alkalizing agent
GB8805268D0 (en) 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
JPH0768125B2 (ja) 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
US4948581A (en) 1989-02-17 1990-08-14 Dojin Iyaku-Kako Co., Ltd. Long acting diclofenac sodium preparation
NZ235877A (en) 1989-11-02 1992-09-25 Mcneil Ppc Inc Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
WO1991016886A1 (en) 1990-05-03 1991-11-14 G.D. Searle & Co. Pharmaceutical composition containing ibuprofen and a prostaglandin
AU7793791A (en) 1990-05-03 1991-11-27 G.D. Searle & Co. Pharmaceutical composition for use in treating pain
ES2071312T3 (es) 1990-05-03 1995-06-16 Searle & Co Composicion farmaceutica.
SE9002206D0 (sv) 1990-06-20 1990-06-20 Haessle Ab New compounds
PL166209B1 (pl) 1990-06-20 1995-04-28 Astra Ab Sposób wytwarzania nowych pochodnych benzimidazolu PL
JP3016829B2 (ja) 1990-07-13 2000-03-06 王子油化合成紙株式会社 オフセット印刷性の優れた塗工樹脂フィルム
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
JPH06506198A (ja) 1991-03-04 1994-07-14 ワーナー−ランバート・コンパニー 種々な剤形の非ステロイド性抗炎症剤の新規な塩/イオン対
US5409709A (en) 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
ES2130152T3 (es) 1991-12-06 1999-07-01 Glaxo Group Ltd Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
DE69231281T2 (de) 1991-12-17 2001-03-01 Biovail Technologies Ltd.(N.D.Ges.D.Staates Delaware), Chantilly Zusammensetzung und verfahren zur ulcusprävention und -behandlung
AU3247593A (en) 1991-12-20 1993-07-28 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
US5294433A (en) 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
GR1002332B (el) 1992-05-21 1996-05-16 Mcneil-Ppc Inc. Νεες φαρμακευτικες συνθεσεις που περιεχουν σιμεθεικονη.
AU4931693A (en) 1992-09-29 1994-04-26 Mcneil-Ppc, Inc. Ibuprofen-h2 antagonist combinations
CA2110313C (en) 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
EP0724441A1 (en) 1993-10-19 1996-08-07 The Procter & Gamble Company Picosulphate dosage form
US5514663A (en) 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US5643960A (en) 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
FR2719999B1 (fr) 1994-05-17 1996-08-02 Georges Serge Grimberg Composition pharmaceutique à base de gomme de guar et d'un antiacide neutralisant, à laquelle peut être ajoutée une série de principes actifs thérapeutiques.
TNSN95062A1 (fr) 1994-05-27 1996-02-06 Astra Ab Nouveaux derives dialkoxy-pyridinyle-benzimidazole
EP0723436B1 (en) 1994-07-08 2001-09-26 AstraZeneca AB Multiple unit tableted dosage form i
US5702723A (en) 1994-08-02 1997-12-30 Griffin; David Multi-stage delivery system for ingestible medications or nutrients
WO1996005199A1 (de) 1994-08-12 1996-02-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazopyridinsalz
CA2197298C (en) 1994-08-13 1999-10-19 Jong Wook Lee Novel pyrimidine derivatives and processes for the preparation thereof
ZA959469B (en) 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
WO1996022780A1 (en) 1995-01-27 1996-08-01 The Board Of Regents Of The University Of Texas System Methods of enhancing the therapeutic activity of nsaids and compositions of zwitterionic phospholipids useful therein
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5955451A (en) 1995-05-12 1999-09-21 The University Of Texas System Board Of Regents Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
AU6981996A (en) 1995-09-27 1997-04-17 Merck Frosst Canada Inc. Compositions for treating inflammation containing certain prostaglandins and a selective cyclooxygenase-2 inhibitor
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20050054682A1 (en) 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
US6231888B1 (en) 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US5925181A (en) 1996-04-08 1999-07-20 Cook; Phillip Michael pH-sensitive modified cellulose ester
US5872145A (en) 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6077539A (en) 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
EP0941101A1 (en) 1996-11-22 1999-09-15 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
CN1238694A (zh) 1996-11-22 1999-12-15 普罗克特和甘保尔公司 治疗肠胃病用的含铋和nsaid的组合物
US6160020A (en) 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
EA002806B1 (ru) 1997-09-11 2002-10-31 Нюкомед Данмарк А/С Многоединичные композиции с модифицированным высвобождением нестероидных противовоспалительных лекарственных веществ (nsaid)
US6040315A (en) 1997-10-30 2000-03-21 Day; Charles E. Antacid co-polymer of guanidine and polyethylenimine
CA2307887A1 (en) 1997-10-31 1999-05-14 Monsanto Company Gellan gum tablet coating
JP4546643B2 (ja) 1997-12-08 2010-09-15 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸不安定な活性化合物を含有する新規の坐剤形
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
DE19801811B4 (de) 1998-01-19 2004-12-23 Stada Arzneimittel Ag Pharmazeutische Zubereitung zur oralen Verabreichung
EP1056456A4 (en) 1998-01-30 2006-10-25 Sepracor Inc R-LANSOPRAZOL COMPOSITIONS AND TREATMENTS THEREFOR
WO1999038512A1 (en) 1998-01-30 1999-08-05 Sepracor Inc. S-lansoprazole compositions and methods
FR2774288B1 (fr) 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
GB9814215D0 (en) 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US6093734A (en) 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
US8231899B2 (en) 1998-09-10 2012-07-31 Nycomed Danmark Aps Quick release pharmaceutical compositions of drug substances
US20020090395A1 (en) 1998-09-10 2002-07-11 Austen John Woolfe Anti-inflammatory pharmaceutical formulations
JP5026635B2 (ja) 1998-09-10 2012-09-12 ニュコメデ ダンマルク アンパーツセルスカブ 医薬物質の迅速放出医薬組成物
US6387410B1 (en) 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
AU757343B2 (en) 1998-09-28 2003-02-20 Capsugel Belgium Nv Enteric and colonic delivery using HPMC capsules
US6485747B1 (en) 1998-10-30 2002-11-26 Monsanto Company Coated active tablet(s)
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
DE19901687B4 (de) 1999-01-18 2006-06-01 Grünenthal GmbH Opioide Analgetika mit kontrollierter Wirkstofffreisetzung
US6183779B1 (en) 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
IL145550A0 (en) 1999-03-26 2002-06-30 Pozen Inc High potency dihydroergotamine compositions
IL145220A0 (en) 1999-05-20 2002-06-30 Par Pharmaceutical Inc Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
SE9902386D0 (sv) 1999-06-22 1999-06-22 Astra Ab New formulation
CA2277407A1 (en) 1999-07-14 2001-01-14 Bernard Charles Sherman Pharmaceutical tablet comprising an nsaid and misoprostol
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6787164B2 (en) 2000-02-23 2004-09-07 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
SE0000773D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US7029701B2 (en) 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US20020045184A1 (en) 2000-10-02 2002-04-18 Chih-Ming Chen Packaging system
US6749867B2 (en) 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
EP1363604A2 (en) 2001-02-14 2003-11-26 Glaxo Wellcome S.A. Pharmaceutical formulation
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US20100172983A1 (en) 2001-06-01 2010-07-08 Plachetka John R Pharmaceutical Compositions for the Coordinated Delivery of Naproxen and Esomeprazole
WO2002098352A2 (en) 2001-06-01 2002-12-12 Pozen Inc. PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
AR036354A1 (es) 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida
US6930099B2 (en) 2001-09-07 2005-08-16 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
FR2845917B1 (fr) 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
US20040121004A1 (en) 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040131676A1 (en) 2002-12-20 2004-07-08 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US7332183B2 (en) 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
WO2004062552A2 (en) 2003-01-09 2004-07-29 Galephar M/F Pharmaceutical composition containing a nsaid and a benzimidazole derivative
WO2004064815A1 (en) 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
JP2005145894A (ja) 2003-11-17 2005-06-09 Takeda Chem Ind Ltd 固形製剤
US20050163847A1 (en) 2004-01-21 2005-07-28 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug
WO2005074930A1 (en) 2004-01-28 2005-08-18 Altana Pharma Ag Pharmaceutical combinations of (s) -pantoprazole with nsaid or corticosteroids
WO2005074536A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
JP2007522217A (ja) 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
US20050227949A1 (en) 2004-04-07 2005-10-13 Nasrola Edalatpour Compositions and methods for treatment of viral and bacterial infections
EP1811975A2 (en) 2004-10-19 2007-08-01 The State of Oregon Acting by and Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
US20060165797A1 (en) 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
US20060178349A1 (en) 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
US20060178348A1 (en) 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a protein extravasation inhibitor and an NSAID
US20060177504A1 (en) 2005-02-08 2006-08-10 Renjit Sundharadas Combination pain medication
EP1726301A1 (en) 2005-05-24 2006-11-29 Flamel Technologies Oral pharmaceutical composition for treating a COX-2 mediated condition
EP1726300A1 (en) 2005-05-24 2006-11-29 Flamel Technologies Oral pharmaceutical formulation for the prevention and/or the treatment of cardiovascular and inflammatory diseases
AR057181A1 (es) 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
EP1965774A2 (en) 2005-12-30 2008-09-10 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
CA2644435C (en) 2006-03-06 2015-04-07 Pozen Inc. Dosage forms for administering combinations of drugs
EP2486910A3 (en) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Multi-chambered apparatus comprising a dispenser head
US20100221336A1 (en) 2007-02-14 2010-09-02 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor
US20080031950A1 (en) 2007-04-27 2008-02-07 Nectid Inc. Novel anelgesic combination
US20090023771A1 (en) 2007-07-18 2009-01-22 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor and protein component
CA2740974A1 (en) 2008-05-30 2009-12-03 Pozen Inc. Dosage forms for the rapid and sustained elevation of gastric ph
CA2736547C (en) 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
EA021112B1 (ru) * 2009-06-25 2015-04-30 Поузен Инк. Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer

Also Published As

Publication number Publication date
EA201491285A1 (ru) 2014-11-28
EA028049B1 (ru) 2017-10-31
CA2860231A1 (en) 2013-07-04
WO2013101897A3 (en) 2015-06-11
EP2797600A2 (en) 2014-11-05
US20170105938A1 (en) 2017-04-20
US20190070118A1 (en) 2019-03-07
US9539214B2 (en) 2017-01-10
MX2014007935A (es) 2014-11-14
UA115139C2 (uk) 2017-09-25
US10603283B2 (en) 2020-03-31
CN104519888A (zh) 2015-04-15
US20140370088A1 (en) 2014-12-18
WO2013101897A2 (en) 2013-07-04
EP2797600A4 (en) 2015-09-16
US9987231B2 (en) 2018-06-05
BR112014016085A8 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
BR112014016085A2 (pt) composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
BR112015012197A2 (pt) terapia de combinação
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
WO2010121128A3 (en) Compositions and methods for treating or inhibiting liver injury
BR112015003796A2 (pt) composição ansiolítica, formulação e método de uso
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
NZ714963A (en) Compositions and methods for treating anemia
BR112013029246A2 (pt) 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
BR112015029401A2 (pt) derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
WO2009051840A3 (en) Compositions and methods for reducing hepatotoxicity associated with drug administration
BR112014029735A2 (pt) forma de dosagem e formulação de abediterol
BR112013033008A8 (pt) composição farmacêutica líquida compreendendo nitisinona
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
BR112014004732A2 (pt) composto benzotiazolona
BR112014016450A2 (pt) composto antagonista de leucotrieno b4
BR112014030288A2 (pt) composição farmacêutica
BR112014011336A2 (pt) composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
BR112015019307A2 (pt) derivados de ácido butanoico substituído com bisfenila como inibidores de nep com eficácia in vivo melhorada

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]